180 Life Sciences (180 Life Sciences) Gross-Profit-to-Asset % : 0.00% (As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is 180 Life Sciences Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. 180 Life Sciences's annualized Gross Profit for the quarter that ended in Mar. 2024 was $0.00 Mil. 180 Life Sciences's average Total Assets over the quarter that ended in Mar. 2024 was $4.35 Mil. Therefore, 180 Life Sciences's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 was 0.00%.

180 Life Sciences Gross-Profit-to-Asset % Historical Data

The historical data trend for 180 Life Sciences's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

180 Life Sciences Gross-Profit-to-Asset % Chart

180 Life Sciences Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Gross-Profit-to-Asset %

180 Life Sciences Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Gross-Profit-to-Asset %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of 180 Life Sciences's Gross-Profit-to-Asset %

For the Biotechnology subindustry, 180 Life Sciences's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

180 Life Sciences's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 180 Life Sciences's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where 180 Life Sciences's Gross-Profit-to-Asset % falls into.

180 Life Sciences Gross-Profit-to-Asset % Calculation

180 Life Sciences's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2023 )	/	( (Total Assets (A: Dec. 2022 )	+	Total Assets (A: Dec. 2023 ))	/ count )
	=	0	/	( (19.65	+	5.259)	/ 2 )
	=	0	/	12.4545
	=	0.00 %

180 Life Sciences's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
	=	0	/	( (5.259	+	3.442)	/ 2 )
	=	0	/	4.3505
	=	0.00 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Mar. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

180 Life Sciences Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of 180 Life Sciences's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

180 Life Sciences (180 Life Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 180 Life Sciences Corp (NAS:ATNFW) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

ATNF:USA

Address

3000 El Camino Real, Bldg. 4, Suite 200, Palo Alto, CA, USA, 94306

Website

https://www.180lifesciences.com

180 Life Sciences Corp is a clinical-stage biotechnology company. It is focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics.